This study will provide long-term follow-up for patients who have received treatment with JCAR015 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of JCAR015 for evaluation of delayed adverse events, presence of persisting JCAR015 vector sequences, and survival.
Long-Term Follow-up Protocol for Subjects Treated With JCAR015
Acute Lymphoblastic Leukemialong-term follow-upchimeric antigen receptor (CAR) T cellsJCAR015
You can join if…
Open to people ages 18 years and up
Patients who have received at least one dose of JCAR015 in a previous treatment protocol.
Patients who have provided informed consent for the long-term follow-up study prior to study participation.
You CAN'T join if...
None. All patients who have previously received JCAR015 treatment are eligible for this long-term follow-up study.
University of California San Francisco, California, 94143, USA